Regulation D Private Placement | Accredited Investors Only
The $195B Telehealth
Opportunity With Proven Operators
Telehealth investment opportunity with 25 years of direct-response marketing expertise and demonstrated revenue growth in a $195B market.
THE OPPORTUNITY
Why Customer Acquisition
Efficiency Matters in Telehealth
Most telehealth companies report customer acquisition costs exceeding $700 per customer. Many are founded by teams learning customer acquisition for the first time, burning investor capital to figure out what works.
PharmaZee founders bring 25 years of proven direct-response marketing experience, having acquired over 1 million customers profitably with their natural health product before entering telehealth.
The result: Customer acquisition costs of $185 compared to industry averages of $700+.
Customer Acquisition Cost
$185 vs. $700+ industry average 4x more efficient
Revenue
Growth
$54K → $173K monthly
12-month period
Market Opportunity
$195B telehealth market
4 major categories
Proven Experience
25 years | 1M+ customers
Direct-response expertise
THE TRACK RECORD
25 Years of Proven Customer Acquisition
Experience creates competitive advantage. PharmaZee founding team spent over two decades building their natural health product to more than 1 million customers using proven direct-response marketing strategies.
This operational expertise—developed through thousands of campaigns, millions in ad spend, and continuous optimization—now applies to the $195B telehealth opportunity.
1999-2024: Building Expertise
Launched their natural health product in 1999
Acquired 1M+ customers profitably over 25 years
Mastered direct-response marketing in health & wellness
Developed repeatable systems for customer acquisition
2024-Present: Applying to Telehealth
Entered telehealth with proven strategies
Achieved $185 customer acquisition cost
Grew monthly revenue from $54K to $173K
Addressing 4 major telehealth categories
THE MARKET
$195 Billion Telehealth
Market Across Four Verticals
PharmaZee addresses four high-demand categories within the rapidly growing telehealth market:
Weight Loss
Including Semaglutide and related treatments Multi-billion dollar category
Sexual Health
Solutions for men and women High-demand, recurring revenue
Dermatology
Common skin condition treatments Accessible, scalable solutions
Mental Health
Support and medications
Growing market need
Each vertical benefits from the same competitive advantage: proven direct-response marketing expertise that delivers customer acquisition costs 4x more efficient than industry benchmarks.
THE TRACTION
Real Performance
Measurable Results
PharmaZee demonstrates operational traction with verified performance metrics:
Monthly Revenue Growth
$54,214 (Jan 2025) → $173,311 (Jan 2026)
Consistent month-over-month growth
Customer Acquisition Efficiency
$185 per customer vs. $700+ industry average
Proven direct-response strategies
Market Validation
4 active telehealth verticals
Diversified revenue streams
Operational Experience
25 years | 1M+ customers acquired
Track record of profitable scaling
This performance reflects the application of proven customer acquisition strategies to a massive market opportunity. The founders aren't learning on investor capital—they're executing a playbook developed over 25 years.
THE COMPETITIVE ADVANTAGE
What Separates PharmaZee From
Other Telehealth Companies
Factor
Most Telehealth Startups
PharmaZee
Founder Experience
Learning customer acquisition
25 years proven expertise
Customer Acquisition Cost
$700+ per customer
$185 per customer
Track Record
First-time operators
1M+ customers acquired
Marketing Expertise
Testing and learning
Proven direct-response systems
Revenue Traction
Pre-revenue or early stage
$54K → $173K monthly growth
Capital Efficiency
High burn to find PMF
Efficient scaling with proven model
Operational experience creates measurable advantages. While many telehealth companies are founded by teams learning customer acquisition for the first time, PharmaZee founders have already mastered profitable customer acquisition in health and wellness.
THE COMPETITIVE ADVANTAGE
What Separates PharmaZee From
Other Telehealth Companies
Factor
Founder Experience
Customer Acquisition Cost
Track Record
Marketing Expertise
Revenue Traction
Capital Efficiency
Most Telehealth Startups
Learning customer acquisition
$700+ per customer
First-time operators
Testing and learning
Pre-revenue or early stage
High burn to find PMF
PharmaZee
25 years proven expertise
$185 per customer
1M+ customers acquired
Proven direct-response systems
$54K → $173K monthly growth
Efficient scaling with proven model
Operational experience creates measurable advantages. While many telehealth companies are founded by teams learning customer acquisition for the first time, PharmaZee's founders have already mastered profitable customer acquisition in health and wellness.
THE INVESTMENT
Investment
Terms & Structure
PharmaZee demonstrates operational traction with verified performance metrics:
INVESTMENT DETAILS
Raise Amount
$1,000,000 SAFE Note
Valuation
$7,000,000 pre-money
Structure
Regulation D Private Placement
Investor Qualification
Accredited Investors Only
Use of Funds:
This capital raise enables PharmaZee to scale what's already working. The founders have demonstrated customer acquisition efficiency and revenue growth. This investment accelerates scaling across four major telehealth categories with proven strategies.
WHY INVEST NOW
The Opportunity: Proven Team Meets Massive Market
The Problem
Most telehealth companies struggle with customer acquisition costs exceeding $700 per customer, making profitability difficult and requiring significant capital to scale.
The Solution
PharmaZee founders bring 25 years of proven direct-response marketing expertise, achieving customer acquisition costs of $185 through strategies developed over decades.
The Timing
The GLP-1/semaglutide market alone is projected to exceed $100B by 2030. PharmaZee is positioned early in this cycle before CAC rises across the industry.
Accredited investors seeking telehealth opportunities with experienced operators, real traction, and efficient unit economics can evaluate PharmaZee investment opportunity through a detailed investor briefing.
RISK FACTORS & DISCLOSURES
Important Investment Disclosures
This is a private securities offering under Regulation D available exclusively to accredited investors. All investments involve risk, including the potential loss of principal.
Early-stage company with limited operating history in telehealth
Competitive market with established players
Regulatory risks in telehealth and healthcare industries
No guarantee of returns or liquidity
Investment suitable only for investors who can afford total loss
Accredited Investor Definition: Individuals with net worth exceeding $1 million (excluding primary residence) or annual income exceeding $200,000 ($300,000 joint) in each of the last two years with expectation of same in current year.
This landing page does not constitute an offer to sell or solicitation of an offer to buy securities. Any such offer or solicitation will be made only through definitive offering documents.
Schedule Your Investor Briefing
Review detailed financials, competitive analysis, growth projections, and investment terms with the founding team.
What You'll Learn:
Detailed customer acquisition strategies and unit economics
Financial performance and growth projections
Competitive positioning and market analysis
Investment structure and terms
Exit strategy and timeline
Q&A with founding team
30-minute briefing | Accredited investors only | No obligation
Confidential
NDA Provided
Regulation D Compliant
PharmaZee
Digital Telehealth Services Platform
Company Information: